PURPOSE: Scintigraphy using (123)I-metaiodobenzylguanidine ((123)I-MIBG) is widely used for the detection of neuroblastic tumours. The aim of this study was to identify a possible correlation between the uptake intensity on (123)I-MIBG SPECT and histopathology of neuroblastic tumours. METHODS: (123)I-MIBG SPECT examinations were performed in 55 paediatric patients with neuroblastic tumour and compared to histopathology after surgical resection or biopsy at a mean of 2 weeks after SPECT. For each lesion International Neuroblastoma Pathology Classification System (INPC) stage, mitosis karyorrhexis index (MKI), location and a semiquantitative tumour-to-liver count-rate ratio (TLCRR) were determined. Also, the presence or absence of MYCN amplification, p1 deletion, urine catecholamine and neuron-specific enolase blood levels at the time of scanning were recorded. RESULTS: In the 55 patients, 61 lesions were evaluated with (123)I-MIBG SPECT and corresponding histopathological findings were reviewed (11 ganglioneuroma, 11 ganglioneuroblastoma and 39 neuroblastoma). TLCRR was significantly higher in the neuroblastoma group (mean TLCRR 2.7) than in the ganglioneuroblastoma group (mean TLCRR 1.0) and ganglioneuroma group (mean TLCRR 0.7) at the time of primary diagnosis (p < 0.001) and at follow-up (p = 0.039). Intense (123)I-MIBG uptake was found in tumour tissue with a high mitotic activity (MKI-high or MKI-intermediate) after treatment. Four ganglioneuromas (36 %), three ganglioneuroblastomas (27 %) and six neuroblastomas (15 %) were (123)I-MIBG-negative. CONCLUSION: In paediatric patients with peripheral neuroblastic tumours, strong (123)I-MIBG uptake indicates unfavourable histopathology. High uptake was seen in neuroblastomas and in tumours with a high mitotic activity.
PURPOSE: Scintigraphy using (123)I-metaiodobenzylguanidine ((123)I-MIBG) is widely used for the detection of neuroblastic tumours. The aim of this study was to identify a possible correlation between the uptake intensity on (123)I-MIBG SPECT and histopathology of neuroblastic tumours. METHODS: (123)I-MIBG SPECT examinations were performed in 55 paediatric patients with neuroblastic tumour and compared to histopathology after surgical resection or biopsy at a mean of 2 weeks after SPECT. For each lesion International Neuroblastoma Pathology Classification System (INPC) stage, mitosis karyorrhexis index (MKI), location and a semiquantitative tumour-to-liver count-rate ratio (TLCRR) were determined. Also, the presence or absence of MYCN amplification, p1 deletion, urine catecholamine and neuron-specific enolase blood levels at the time of scanning were recorded. RESULTS: In the 55 patients, 61 lesions were evaluated with (123)I-MIBG SPECT and corresponding histopathological findings were reviewed (11 ganglioneuroma, 11 ganglioneuroblastoma and 39 neuroblastoma). TLCRR was significantly higher in the neuroblastoma group (mean TLCRR 2.7) than in the ganglioneuroblastoma group (mean TLCRR 1.0) and ganglioneuroma group (mean TLCRR 0.7) at the time of primary diagnosis (p < 0.001) and at follow-up (p = 0.039). Intense (123)I-MIBG uptake was found in tumour tissue with a high mitotic activity (MKI-high or MKI-intermediate) after treatment. Four ganglioneuromas (36 %), three ganglioneuroblastomas (27 %) and six neuroblastomas (15 %) were (123)I-MIBG-negative. CONCLUSION: In paediatric patients with peripheral neuroblastic tumours, strong (123)I-MIBG uptake indicates unfavourable histopathology. High uptake was seen in neuroblastomas and in tumours with a high mitotic activity.
Authors: Edward F Attiyeh; Wendy B London; Yael P Mossé; Qun Wang; Cynthia Winter; Deepa Khazi; Patrick W McGrady; Robert C Seeger; A Thomas Look; Hiroyuki Shimada; Garrett M Brodeur; Susan L Cohn; Katherine K Matthay; John M Maris Journal: N Engl J Med Date: 2005-11-24 Impact factor: 91.245
Authors: K K Matthay; C Perez; R C Seeger; G M Brodeur; H Shimada; J B Atkinson; C T Black; R Gerbing; G M Haase; D O Stram; P Swift; J N Lukens Journal: J Clin Oncol Date: 1998-04 Impact factor: 44.544
Authors: Henriette Ingrid Melzer; Eva Coppenrath; Irene Schmid; Michael H Albert; Dietrich von Schweinitz; Coral Tudball; Peter Bartenstein; Thomas Pfluger Journal: Eur J Nucl Med Mol Imaging Date: 2011-05-27 Impact factor: 9.236
Authors: G M Brodeur; J Pritchard; F Berthold; N L Carlsen; V Castel; R P Castelberry; B De Bernardi; A E Evans; M Favrot; F Hedborg Journal: J Clin Oncol Date: 1993-08 Impact factor: 44.544
Authors: P S White; J M Maris; C Beltinger; E Sulman; H N Marshall; M Fujimori; B A Kaufman; J A Biegel; C Allen; C Hilliard; M B Valentine; A T Look; H Enomoto; S Sakiyama; G M Brodeur Journal: Proc Natl Acad Sci U S A Date: 1995-06-06 Impact factor: 11.205
Authors: Steven G DuBois; Rajen Mody; Arlene Naranjo; Collin Van Ryn; Douglas Russ; Derek Oldridge; Susan Kreissman; David L Baker; Marguerite Parisi; Barry L Shulkin; Harrison Bai; Sharon J Diskin; Vandana Batra; John M Maris; Julie R Park; Katherine K Matthay; Gregory Yanik Journal: Pediatr Blood Cancer Date: 2017-04-06 Impact factor: 3.167
Authors: Wolfgang Peter Fendler; Vera Wenter; Henriette Ingrid Thornton; Harun Ilhan; Dietrich von Schweinitz; Eva Coppenrath; Irene Schmid; Peter Bartenstein; Thomas Pfluger Journal: PLoS One Date: 2015-07-15 Impact factor: 3.240
Authors: Laura Privitera; Patrick W Hales; Layla Musleh; Elizabeth Morris; Natalie Sizer; Giuseppe Barone; Paul Humphries; Kate Cross; Lorenzo Biassoni; Stefano Giuliani Journal: J Magn Reson Imaging Date: 2020-12-06 Impact factor: 5.119